A common mutation C677T in the 5,10-methyltetrahydrofolate reductase gene is associated to idiopathic deep venous thrombosis;La mutation C677T du gène de la 5,10-méthylté trahydrofolate réductase est associée aux thromboses veineuses idiopathiques

Revue de Medecine Interne

Volumn 24, Issue 9, 2003, Pages 569-576

  Berrut, G ^a   Ghali, A ^a   Quere, I ^b   Ternisien, C ^a   Gallois, I ^a   Roy, P M ^a   Marre, M ^c   Fressinaud, P ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Deep venous thrombosis; Homocysteine; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase (MTHFR)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; EVALUATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

EID: 0041874732     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00210-8     Document Type: Article

References (60)

1. Frost P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in MTHFR. Nature Genet 1995;10:111-3.
2. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998;95:13217-20.
3. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13.
4. Herrman W, Quast S, Ullrich M, Schultze H, Bodis M, Geisel J. Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 1999;144:91-101.
5. Mcquillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 1999;99:2383-8.
6. Wilken DEL, Wilcken B. The pathogenesis of coronary artery disease: A possible role for methionine metabolism. J Clin Invest 1976;57:1079-82.
7. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JCM, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam study. Arch Intern Med 1999;159:38-44.
8. Zittoun J. Homocystéine et pathologie vasculaire. Hématologie 1998;4:7-16.
9. Fermo I, Vigano' D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
10. Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev 1992;12:279-98.
11. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
12. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101-6.
13. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-3.
14. Arruda VR, Siqueira LH, Gonçalves MS, von Zuben PM, Soares MCP, Menezes R, et al. Prevalence of the mutation C677→T in the methylenetetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet 1998;78:332-5.
15. Franco RF, Araújo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998;79:119-21.
16. Munoz-Moran E, Dieguez-Lucena JL, Fernandez-Arcas N, Peran-Mesa S, Reyes-Engel A. Genetic selection and folate intake during pregnancy. Lancet 1998;352:1120-1.
17. Heijmans BT, Gussekloo J, Kluft C, Droog S, Lagaay AM, Knook DL, et al. Mortality risk in men is associated with a common mutation in the methylenetetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet 1999;7:197-204.
18. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-45.
19. Kang SS, Zhou J, Wong PWK, Kovalisyn J, Strokosch G. Intermediate homocysteinemia: A Thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-21.
20. Kluijtmans LAJ, van den Heuvel PWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
21. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032-6.
22. Hegele RA, Tully C, Young TK, Connelly PW. V677 mutation of methylenetetrahydrofolate reductase and cardiovascular disease in Canadian Inuit. Lancet 1997;349:1221-2.
23. Arai K, Yamasaki Y, Kajimoto Y, Watada H, Umayahara Y, Kodama M, et al. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes 1997;46:2102-4.
24. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Yazaki Y, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc biol 1998;18:1465-9.
25. Harmon DL, Doyle RM, Meleady R, Doyle M, Shields DC, Barry R, et al. Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 1999;19:208-11.
26. Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKA, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;21(346): 1070-1.
27. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999;84:151-7.
28. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, et al. A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. Q J Med 1995;88:763-6.
29. Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, et al. 5,10-methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Genet 1996;63:610-4.
30. van der Put NMJ, van den heuvel LP, Steegers-Theunissen RP, Trijbels FJ, Eskes TK, Mariman EC, et al. Decreased methylenetetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring. J Mol Med 1996;74:691-4.
31. Mills JL, Kirke PN, Molloy AM, Burke H, Conley MR, Lee YJ, et al. Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. Am J Med Genet 1999;86:71-4.
32. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Genet 1997;19(74):526-8.
33. Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorphysm as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998;352:454.
34. Nelen WLD, Steegers EAP, Eskes TKA, Blom HJ. Genetic risk factor for unexplained reccurent early pregnancy loss. Lancet 1997;350:861.
35. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-65.
36. Salomon O, Moisseiev J, Rosenberg N, Vidne O, Yassur I, Zivelin A, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis 1998;9:617-22.
37. Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical importance. Gut 1999;45:389-94.
38. Margaglione M, D'andria G, d'Addedda M, Giuliani N, Cappuci G, Iannaccone L, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the Prothombin A 20210 mutation. Thromb Haemost 1998;79:907-11.
39. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The Mutation Ala677→Val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997;77:818-21.
40. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511-8.
41. Couturaud F, Oger E, Abalain JH, Chenu E, Guias B, Floch HH, et al. Methylenetetrahydrofolate reductase C677T genotype and venous thromboembolic disease. Respiration 2000;67(6):657-61.
42. 506). Arterioscler Thromb Vasc Biol 1997;17:1662-6.
43. Kluijtmans LAJ, Boers GHJ, Verbruggen B, Trijbels FJM, Novácová IRO, Blom HJ. Homozygous cystathionine β-synthase deficiency combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of deep venous thrombosis. Blood 1998;91:2051-8.
44. Fujimura H, Kawasaki T, Sakata T, Ariyoshi H, Kato H, Monden M, Miyata T. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thromb Res 2000;98(1):1-8.
45. Ocal IT, Sadeghi A, Press RD. Risk of venous Thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase. Mol Diagn 1997;2:61-8.
46. Vargas M, Soto I, Pinto CR, Urgelles MF, Coto E. Mild hyperhomocysteinemia and MTHFR C677T do not increase the risk for venous thrombosis in a Spanish population, Blood Coagul Fibrinolysis 1998;9:555-6.
47. Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep venous thrombosis. Thromb Haemost 1998;79:254-8.
48. Quéré I, Chassé JF, Dupuy E, Bellet E, Molho-Sabatier P, Tobelem G, Jambon C. Homocystéine, 5,10-mé thylènetétrahydrofolate réductase et thrombose veineuse profonde. Enquète auprès de 120 patients en médecine interne. Rev Méd Interne 1998;19:29-33.
49. Quéré I, Pemeger TV, Zittoun J, Bellet H, Gris JC, Daures JP, et al. Red blood methylfolate and plasma homocysteine as risk factors to venous thromboembolism: a matched case-control study. Lancet 2002;359:747-52.
50. Varela ML, Adamczuk YP, Forastiero RR, Martinuzzo ME, Cerrato GS, Pombo G, Carreras LO. Major and potential prothrobotic genotypes in a cohort of patients with venous thromboembolism. Thromb Res 2001;104(5):317-24.
51. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med 1998;128:663-77.
52. Klearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparision of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
53. Emmerich J. Thromboses veineuses profondes des membres inférieurs. Rev Prat 1999;49:901-7.
54. Ville L, Roger M. S Les thromboses veineuses profondes, sous traitement anticoagulant préventif, chez des personnes âgées de plus de 70 ans. Sem Hôp Paris 1998;74:821-8.
55. Emmerich J. Mécanismes et facteurs de risque de la maladie veineuse thromboembolique. Rev Prat 1996;46:1203-10.
56. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1993;353:1167-73.
57. Brattsom L, Zhang Y, Hurtig MTHFR, Refsum H, Östenson S, Fransson L, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclersis 1998;141:315-9.
58. McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylenetetrahydrofolate reductase in african americans. Thrombosis Res 1996;83:195-8.
59. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
60. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B 12, and folate. Am J Epidemiol 1996;143:845-59.